Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Talimogene laherparepvec induces durable response of regionally advanced Merkel cell carcinoma in 4 consecutive patients.

Westbrook BC, Norwood TG, Terry NLJ, McKee SB, Conry RM.

JAAD Case Rep. 2019 Aug 29;5(9):782-786. doi: 10.1016/j.jdcr.2019.06.034. eCollection 2019 Sep. No abstract available.

2.

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.

Johnson DB, Bordeaux J, Kim JY, Vaupel C, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy J, Witte JS, McKee SB, Ko J, Wrangle JM, Dabbas B, Tangri S, Lameh J, Hall J, Markowitz J, Balko JM, Dakappagari N.

Clin Cancer Res. 2018 Nov 1;24(21):5250-5260. doi: 10.1158/1078-0432.CCR-18-0309. Epub 2018 Jul 18.

3.

Smoldering myocarditis following immune checkpoint blockade.

Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, Gertler AS, Moslehi JJ, Conry RM.

J Immunother Cancer. 2017 Nov 21;5(1):91. doi: 10.1186/s40425-017-0296-4.

4.

Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases.

Everett AS, Pavlidakey PG, Contreras CM, De Los Santos JF, Kim JY, McKee SB, Kaufman HL, Conry RM.

J Cutan Pathol. 2018 Jan;45(1):48-53. doi: 10.1111/cup.13048. Epub 2017 Oct 26.

PMID:
28940544
5.

Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec.

Blackmon JT, Stratton MS, Kwak Y, Pavlidakey PG, Slominski AT, McKee SB, Viator TM, Kim JY, Huang CC, Conry RM.

JAAD Case Rep. 2017 Jun 16;3(4):280-283. doi: 10.1016/j.jdcr.2017.02.011. eCollection 2017 Jul. No abstract available.

6.

Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab.

Kropp LM, De Los Santos JF, McKee SB, Conry RM.

J Immunother. 2016 Nov/Dec;39(9):373-378.

Supplemental Content

Loading ...
Support Center